

Cascadero Copper to raise up to \$1 million in non brokered private placement

Cascadero Copper Corp {TSX.V: CCD} announced a non-brokered private placement of up to 10,000,000 Units at C\$0.10 per Unit for gross proceeds of \$1,000,000.

Each Unit consists of one Common Share and one Common Share Purchase Warrant. at C\$0.15 per share.

Non-Brokered Private Placement Announcement

Non-Brokered Private Placement

Cascadero Copper Corp {TSX.V: CCD} announced a non-brokered private placement of up to 10,000,000 Units at C\$0.10 per Unit for gross proceeds of \$1,000,000.

Each Unit consists of one Common Share and one Common Share Purchase Warrant. One Common Share Purchase Warrant entitles the holder to purchase one Common Share at C\$0.15 per share for a two (2) year term from closing. The units are subject to a 121-day hold period from closing.

Finder fees are payable. The Common Share Purchase Warrant is not transferrable and will subject to a standard Accelerated Exercise Clause.

Completion of the financing is subject to regulatory approval, including acceptance of the financing by the TSX Venture Exchange.

Subject to closing the 10,000,000 unit offering, Cascadero will have 179,806,195 million shares issued. Cascadero intends to use the proceeds for continued exploration on its Argentine properties.

Contact:

Bill McWilliam President and CEO

Cascadero Copper Corp.

+1 604 999 0391Neither the TSX Venture Exchange nor its Regulation Service Provider accepts responsibility for the adequacy or accuracy of this release.

Barkerville Gold Mines Announces C\$10,070,000 Million Flow-Through Share Private Placement

Barkerville Gold Mines Ltd. {TSX.V: BGM} announced that it has entered into an agreement with Canaccord Genuity as lead agent on behalf of a syndicate of agents, in connection with a proposed fully-marketed private placement to raise aggregate gross proceeds of up to C\$10,070,000.

Barkerville Gold Mines Announces C\$10,070,000 Million Flow-Through Share Private Placement

November 22nd, 2016

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario – November 22, 2016 – **Barkerville Gold Mines Ltd. {TSX.V: BGM}** is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord”), as lead agent on behalf of a syndicate of agents (collectively, the “Agents”), in connection with a proposed fully-marketed private placement to raise aggregate gross proceeds of up to C\$10,070,000 (the “Offering”).

The Offering will consist of the sale of up to 13,400,000 flow-through common shares of the Company (the “Tranche A Flow-Through Shares”) at a price of C\$0.60 per Tranche A Flow-Through Share and the sale of up to 3,500,000 flow-through common shares of the Company (the “Tranche B Flow-Through Share”) at a price of C\$0.58 per Tranche B Flow-Through Share.

The closing of the Offering is expected to occur on or about December 19, 2016 and is subject to the completion of formal documentation and receipt of regulatory approvals, including the approval of the TSX Venture Exchange.

The gross proceeds received by the Company from the Offering will be used to incur Canadian exploration expenses on the Company’s properties in the Province of British Columbia that are “flow-through mining expenditures” (as such terms are defined in the Income Tax Act (Canada)) (the “Qualifying Expenditures”). The Qualifying Expenditures will be renounced to the subscribers with an effective date no later than December 31, 2016, in the aggregate amount of not less than the total amount of the gross proceeds raised from the Offering.

The securities offered have not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

About Barkerville Gold Mines Ltd.

Barkerville Gold Mines Ltd. is engaged in the exploration and production of precious metals from mineral tenures located in the Cariboo Mining District in east-central British Columbia. The Company presently controls 211,900 hectares of mineral tenures, including three historic groups of contiguous Crown-Granted mineral claims, namely the Cariboo Gold Quartz Group, Island Mountain Group, and Mosquito Creek Group. This large block of contiguous mineral tenures is roughly centered around the town of Wells, which is located approximately 85 km east of Quesnel, British Columbia.

This contiguous block represents about 75% of the complete mineral tenures package. The Company's QR Mine & Mill are located approximately 58 km southeast of Quesnel, on a separate group of mineral tenures. Outside of these areas, the Company has a further 5 blocks of mineral tenures located in and around these two areas. These areas were acquired by staking in late 2015 based on regional target generation completed in 2015. The mineral tenures encompass seven past producing hard rock mines, including the QR Mine & Mill.

The Cariboo Gold Belt has had a rich and extensive history starting with the discovery of placer gold in the 1860's. Recorded production from the Company's property and surrounding area is approximately 3.2 million ounces of placer gold and 1.3 million ounces of lode gold averaging 0.40 oz/t gold from mainly mesothermal quartz vein mineralisation, and 0.60 oz/t from sulphide replacement style mineralisation. Mining of these deposits took place during the periods 1933 to 1967 and 1983 to 1987.

Barkerville Gold Mines has attracted approximately \$55 million in new investment since the beginning of 2015 and now has a technically and financially supportive major shareholder base consisting of Eric Sprott (19%), Osisko Mining (17%) and Osisko Gold Royalties (16%).

For more information on Barkerville Gold Mines Ltd., please contact:

Chris Lodder
President & Chief Executive Officer
Suite 400-365 Bay Street
Toronto, Ontario, Canada
cloodder@barkervillegold.com

Cautionary Statement on Forward-Looking Information

Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy

of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company's objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Inovio's Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced that Dr. David B. Weiner, its co-founder, board member and chair of its scientific advisory board, has been selected as a "Top 20 Translational Researcher" for the year 2015 by the editors of *Nature Biotechnology* magazine.

The selection is based on the number of medical innovations that led to patents a researcher was granted in a calendar year.

Inovio's Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher

Dr. David B. Weiner recognized for his innovative medical and scientific research, which has been the basis for over 100 patents

PLYMOUTH MEETING, Pa. – November 21, 2016 – **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** today announced that Dr. David B. Weiner, its co-founder, board member and chair of its scientific advisory board, has been selected as a "Top 20 Translational Researcher" for the year 2015 by the editors of *Nature Biotechnology* magazine.

The selection is based on the number of medical innovations that led to patents a researcher was granted in a calendar year. The designation “translational researcher” refers to basic research that can move from the lab bench to become patented medicine.

Dr. Weiner’s patented innovations relate to advancing the field of DNA-based immunotherapies targeting challenging infectious diseases and cancers. Over his career he holds more than 100 issued and pending U.S. patents. From 1986 until 2015, Dr. Weiner’s lab was at the University of Pennsylvania, Perelman School of Medicine. In 2016, Dr. Weiner joined The Wistar Institute, the nation’s first independent biomedical research institute, an NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “*This award acknowledges David’s innovation and commitment to creating tomorrow’s medicines with a revolutionary technology, DNA-based immunotherapies and vaccines, which Inovio is developing in early and late-stage clinical trials. While I can say I am personally proud of my association with Dr. Weiner, which is now decades long, I can also say that we at Inovio as a team have tremendous respect and appreciation for his innovation and dedication to this field and congratulate him on this award.*”

About Dr. David B. Weiner

Dr. Weiner is a world-renowned leader in immunology as well as gene vaccines and immunotherapy. In scientific circles he is known as the “father of DNA vaccines.” He has more than 350 peer-reviewed publications in scientific journals, including mainstream publications such as *Scientific American*, and has been designated by the Institute for Scientific Information as

one of the top-cited scientists in the world. An inventor of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director's Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children's Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy.

David Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati, and a B.S. in biology from SUNY at Stony Brook in Stony Brook, N.Y.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells *in vivo* in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:

Bernie Hertel

+1 858-410-3101

bhertel@inovio.com

Condor Gold “buy” rating confirmed by Numis Securities

Condor Gold PLC {AIM: CNR}’s stock had its “buy” rating reaffirmed by equities researchers at Numis Securities Ltd in a research report issued on Friday

They currently have a £1.30 (\$1.62) price target on the stock. Numis Securities Ltd’s price target would indicate a potential upside of 124.14% from the company’s current price.

I’m not a great fan of this sort of research, and it’s a strange time to publish when the gold price has fallen back so much.

Maybe they felt the stock needed a boost after it’s nearly 50% recent fall?

The timing of these reports can often be questioned,

Strongbow South Crofty Water Treatment Trials Commence

Strongbow Exploration Inc. {TSX-V: SBW} provided an update on its 100% owned South Crofty Tin Project:

Water treatment trials have now commenced and all surface planning pre-commencement conditions were satisfied on time.

Strongbow South Crofty Water Treatment Trials Commence

Surface Planning Conditions Satisfied

Strongbow Exploration Inc. {TSX-V: SBW} is pleased to provide the following update on its 100% owned South Crofty Tin Project:

Highlights:

Water treatment trials have now commenced at the South Crofty mine

All surface planning pre-commencement conditions satisfied on time

Application has been made to Cornwall Council for a Certificate of Lawfulness of Proposed Use or Development – this is expected to be granted before year end

Water Treatment Trials

Water treatment trials have commenced at South Crofty. The purpose of the testing is to demonstrate that suspended solids and metals in solution, principally iron oxide, in the historical South Crofty mine water can be successfully

treated, reducing metal content to allow safe discharge of the water into the nearby Red River. Untreated mine water is presently discharging continuously into the Red River, so the proposal to treat the water during the dewatering phase represents a significant improvement over the current conditions of the Red River environment.

The large scale trial will treat 18 cubic metres per hour of mine water. This trial will utilise Siltbuster Processing Solutions' High Density Sludge process (HDS). This will provide performance data for both the design of the full-scale plant and to support the Company's Discharge Consent permit application. The trial is expected to last two to three months and will allow the permit application process to begin in Q1 2017. After completion of the tests the Company intends to apply for a permit to treat and discharge up to 25,000 cubic metres of mine water per day. This will allow the mine to be dewatered over an 18 – 24 month period.

Similar treatment facilities are already in place at the nearby former Wheal Jane tin mine, and have been operating successfully since 2000.

Surface Planning Permissions / Conditions Satisfied

The South Crofty mine benefits from having full Conditional Planning Permission to build new surface infrastructure and processing facilities in order to support future underground mining operations. The Planning Permission was granted in November 2011. There were seven pre-commencement conditions that needed to be satisfied and discharged before the permission could be implemented. All seven pre-conditions were satisfied by the Company and discharged by Cornwall Council on

14th October 2016. Construction work required to implement the planning permission was commenced and completed prior to the deadline of 3rd November 2016. The Company has now applied to Cornwall Council for a Certificate of Lawfulness of Proposed Use or Development and expects it to be granted before year end.

Richard Williams, the Company's CEO, stated "*We continue to make good progress de-risking South Crofty and are hopeful we can get to the point where we are in a position to make a production decision. Implementing the Planning Permission was a critical step and we are very pleased to have completed this requirement on time. The next steps for us are the completion of the water treatment test work and related application to treat and discharge the mine water as well as publication of the Preliminary Economic Assessment. These are both scheduled for Q1, 2017.*"

About South Crofty

The South Crofty tin project comprises an Underground Mine Permission area that covers 1,490 Hectares, an area which includes twenty six (26) former producing mines. Production records go back to 1592, but full-scale mining activities commenced in the mid-17th century. The mine closed in 1998 as a result of the tin price collapse of 1985 and impending changes to mining laws and liabilities in the late 1990s.

A new Mine Permit was granted in 2013, and is valid until 2071.

Strongbow acquired the project from administration (receivership) in July 2016 (see news release dated July 12,

2016), following the publication of a new NI 43-101 Mineral Resource Estimate (see news releases dated April 19, June 1, and July 20, 2016).

The NI 43-101 Mineral Resource Estimate comprises two zones:

1. A Lower Mine tin-only resource;

Lower Mine Mineral Resource Estimate at 0.60% Sn Cut-Off
Tonnes ('000s) Sn Grade Contained Sn (tonnes)

Indicated Resource 1,660 1.81% 30,000

Inferred Resource 738 1.91% 14,100

2. An Upper Mine polymetallic resource, comprising tin, copper and zinc:

Upper Mine Mineral Resource Estimate at 0.60% SnEq Cut-off
(1-12)

Tonnes (k) Sn % Cu % Zn % SnEq %

Indicated Resource

257 0.70 0.79 0.58 0.99

Inferred Resource 464 0.67 0.62 0.63 0.91

Additional detail can be accessed from the NI 43-101 Technical Report on the Company's SEDAR page or from Strongbow's website at www.strongbowexploration.com

key notes are provided below:

CIM definitions were followed for Mineral Resources.

The Qualified Persons for this Mineral Resource estimate are: Richard Routledge, M.Sc. (Applied), P.Geo. and Eugene Puritch, P.Eng. of P&E Mining Consultants Inc.

Mineral Resources are estimated by conventional 3D block modelling based on wireframing at a 0.50% SnEq cut-off grade and inverse distance to the power of 3 grade interpolation. The 0.5% Sn/SnEq cut-off for wireframing vs 0.6% Sn/SnEq cut-off for resource reporting is due to a shift to lower Sn prices between the commencement and finalisation of this

report.

SnEq is calculated using the formula: %SnEq = Sn% + (Cu% x 0.311) + (Zn% x 0.084).

For the purpose of resource estimation, assays were capped at 20% Sn for the Lower Mine and 6% for Sn, 4% for Cu and 20% for Zn for the Upper Mine.

The 0.6% Sn/SnEq resource cut-off grade was derived from the approximate March 31, 2016 two year LME trailing average Sn price of US\$8.50/lb, Cu price of US\$2.75/lb, and Zn price of US\$0.90/lb, 88.5%, 85% and 70% respective process recoveries, smelter payable of 95% and Sn refining charges of US\$0.25/lb. Operating costs used were US\$55/t mining, US\$27/t processing and US\$9/t G&A.

Bulk densities of 2.77 tonnes/m³ and 3.00 tonnes/m³ have been applied for volume to tonnes conversion for the Lower and Upper Mine, respectively.

Mineral Resources are estimated from near surface to a depth of approximately 869 m. Mineral Resources are classified as Indicated and Inferred based on drill hole and channel sample distribution and density, interpreted geologic continuity and quality of data.

The mineral resources have been depleted for past mining, however, they contain portions that may not be recoverable pending a future engineering study.

Mineral resources which are not mineral reserves do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. There is no certainty that all or any part of the Inferred Mineral Resource will be upgraded to an Indicated or Measured Mineral Resource as a result of continued exploration.

Figures in table are rounded and may not sum exactly.

About the Tin Market

Approximately 350,000 tonnes of tin is consumed annually worldwide. Close to 50% of the tin is used in high tech electronics, mainly in the form of lead-free solder. Major producers of tin include China, Indonesia, Peru, Bolivia and Myanmar. In 2016, the tin price has increased from a low point of US\$13,000 / tonne (US\$5.91 / lb) in January to its current level of approximately US\$20,000 / tonne (US\$9.09 / lb)

For more information on tin, please visit <https://www.itri.co.uk>

(the International Tin Research Institute).

Inovio Wins Deloitte's Prestigious "Fast 500" Growth Award

Inovio Pharmaceuticals, Inc. {NASDAQ: INO}, announced it ranked No. 107 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.

Inovio Wins Deloitte's "Fast 500" Growth Award

Developer of DNA-based Immunotherapies Recognized For its Ability to Attract Grants and Partnerships

PLYMOUTH MEETING, Pa. – November 16, 2016 – **Inovio Pharmaceuticals, Inc.** {NASDAQ: INO}, today announced it ranked No. 107 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.

Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. During this period Inovio's revenue growth reached 885.1%, based on revenue received from grants, partnerships and licensing deals.

Dr. J. Joseph Kim, Inovio's President and CEO, said, “*We appreciate Deloitte's recognition of Inovio's growth based on our advancement of DNA immunotherapies and vaccines for cancers and infectious diseases. Our growth is fueled by the innovative spirit of our scientists, engineers and business people. At our company's core; however, the Inovio team is motivated by our most important value: “Patients are waiting.”*

“This year's Fast 500 winners showcase that when organizations are open to diverse perspectives and insights, they are able to create an environment for their employees and investors to see the possibilities and ingenious solutions that might lie ahead,” added Jim Atwell, Deloitte's national managing partner of the emerging growth practice. “Entrepreneurial environments foster change and innovation within businesses, and we look forward to watching these companies continue to drive change across all sectors.”

About Deloitte's 2016 Technology Fast 500™

Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015. Overall, 2016 Technology Fast 500™ companies achieved revenue growth ranging from 121 percent to 66,661 percent from 2012 to 2015, with median growth of 290 percent.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least \$50,000 USD, and current-year operating revenues of at least \$5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells *in vivo* in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:

Bernie Hertel

Inovio Pharmaceuticals

+1 858-410-3101

bhertel@inovio.com

Scorpio Gold Reports High Gold Values in Phase 1 Soil Sampling at Goldwedge, Nevada

Scorpio Gold Corp. {TSX.V: SGN} reported results from Phase 1 of its 2016 soil sampling program in the Keystone-Jumbo project area at its 100% owned Goldwedge property.

Scorpio Gold Reports High Gold Values in Phase 1 Soil Sampling at the Goldwedge Property, Nevada

Vancouver, November 14, 2016 – **Scorpio Gold Corp.** {TSX-V: SGN} is pleased to report results from Phase 1 of its 2016 soil sampling program in the Keystone-Jumbo project area at its 100% owned Goldwedge property.

Scorpio Gold initiated a three-phased soil sampling program and ground magnetic/VLF electromagnetic survey over the Keystone-Jumbo project area in mid-2016. The geophysical survey was designed to assist in structural interpretation of the area and utilized 50 meter line spacing to provide high resolution of structural breaks. The soil sampling program is being conducted at 100 meter sampling intervals to detect anomalous gold mineralisation in areas covered by overburden. In the Keystone-Jumbo area, overburden covers approximately 85% of the land position and typically ranges from 0 to 2 meters depth.

Phase 1 of the soil sampling program was conducted over the main area of interest that surrounds the historic Keystone and Jumbo mine workings. Geochemical analyses of the 149 samples collected have produced very promising results (Table 1). The original success criterion for this program was considered to be the discovery of a >15 ppb gold ("Au") soil anomaly. ***For reference, the average crustal abundance in this area is 1-5 ppb Au.***

Table 1. Phase 1 Soil Sampling Program – Samples Returning ≥ 50 ppb Au

B Samples (2-80 mesh)		C Samples (+80 mesh)	
Sample ID	Au (ppb)	Sample ID	Au (ppb)
GWSS-16-0017B	59.1	GWSS-16-0038C	86.8
GWSS-16-0022B	2640.1	GWSS-16-0042C	63.6
GWSS-16-0038B	132.7	GWSS-16-0058C	191.5
GWSS-16-0042B	75.9	GWSS-16-0070C	83.8
GWSS-16-0052B	409.1	GWSS-16-0078C	59.1
GWSS-16-0058B	216.1	GWSS-16-0079C	63.9
GWSS-16-0069B	62.2	GWSS-16-0081C	153.4

GWSS-16-0070B 85.6 GWSS-16-0082C 138.5
GWSS-16-0081B 457.1 GWSS-16-0098C 117.0
GWSS-16-0082B 101.9 GWSS-16-0106C 75.2
GWSS-16-0098B 97.1 GWSS-16-0117C 60.9
GWSS-16-0099B 83.6 GWSS-16-0132C 75.4
GWSS-16-0106B 90.7
GWSS-16-0117B 231.0
GWSS-16-0124B 50.2
GWSS-16-0132B 2844.7

The Phase 1 sampling results are particularly promising in light of the structural interpretation from the magnetometer survey. Results to date outline a 1,100 meter long soil anomaly that follows a distinct N30-45W trending structural break. This trend sub-parallels the N30W structure mapped in the Keystone pit, which is determined to be the main structural control to mineralisation. These data correlate well with Scorpio Gold's surface geological mapping that has identified previously unknown NW trending structures in the same corridor. Documentation of prior exploration work does not recognise these significant structures, and they have yet to be tested despite the decades of prospecting in the region. Step-out soil sampling, additional detailed mapping and modeling is underway in support of actionable exploration targets within the mineralised corridor.

Phase 2 of the sampling program (completed) and Phase 3 (ongoing) will cover the remainder of the Keystone-Jumbo project area that was not subjected to ground disturbance during historical mining operations. Results will be released once received and compiled.

Plan maps showing the structural interpretation, soil sampling grids and results to date can be viewed in the following links.

Sampling Grids & Structural Interpretation: Grids & Structures

Phase 1 Soil Samples > 50 ppb from B fraction (2-80 mesh): B Samples

Phase 1 Soil Samples > 50 ppb from C fraction (+80 mesh): C Samples

The Jumbo and Keystone deposits are located approximately 4 km southeast of the Company's Goldwedge deposit. The Keystone open pit was mined by Nevada Goldfields in 1990 and reported 5,750 ounces recovered at 0.32 opt gold. The Jumbo underground mine/pit has no historically reported recovered gold ounces associated with it. New Concept Mining reported mineral resource estimates for both the Jumbo and Keystone deposits in May 1997; however, neither estimate is compliant with NI 43-101 and await verification.

Soil Samples – B and C Fractions

The soil samples are sieved into three size fractions, coarser than 2 mesh (A Sample), 2 mesh to 80 mesh (B Sample) and finer than 80 mesh (C Sample). The A samples were retained as a lithological reference, while the B and C samples were analyzed for both Au and tracer elements. The C samples are considered to be the better indicators for Au mineralization as Au is preferentially adsorbed onto clay minerals and the finer particle size reduces statistical errors and nugget effect. The coarser B samples, while also indicative for Au, are better representatives of geochemical tracer elements such as As, Hg, Sb, as their associated minerals are part of the host rock alteration assemblage that is better sampled using a coarser fraction.

Soil samples were prepped at Bureau Veritas in Reno, Nevada and pulps analysed at Bureau Veritas, Vancouver. Both are ISO 9001 certified testing laboratories and operate in compliance with ISO/IEC 17025:2005 standards. Further details are presented in the Company's quality assurance and quality control program for the Keystone-Jumbo project, available at: QAQC-KJ.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is currently in production as a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.

Scorpio Gold's Chairman, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Chris Zerga,
President

Inovio's Cancer (INO-3112) Generates T Cell Immune Responses in Tumor Tissue in Patients with HPV

Inovio Pharmaceuticals, Inc. {NASDAQ: INO}, announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T-cell responses measured both in tumor tissue and in peripheral blood from subjects with head and neck cancer associated with human papillomavirus (HPV).

Inovio's Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer

Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study

PLYMOUTH MEETING, Pa. – November 14, 2016 – **Inovio Pharmaceuticals, Inc.** {NASDAQ: INO}, today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T-cell responses measured both in tumor tissue and in peripheral blood from subjects with head and neck cancer associated with human papillomavirus (HPV).

The immunology results show that INO-3112 treatment generated robust HPV16/18 specific CD8+ T cell responses in peripheral

blood in four of five subjects who also showed increased T-cell activation in resected tumor tissue samples. These four subjects remained disease free in continuing follow-up that ranged from nine to 24 months at the time of analysis. One subject with only minimal increases in T cell immune responses developed progressive disease at 11 months post start of the study. These results were presented November 12th at the 2016 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "In immuno-oncology, it's all about the T cells. We now have evidence in cancer patients that our immunotherapy product can generate antigen-specific CD8+ killer T cell responses in the tumor, a major step forward towards an effective immunotherapy. This study gives us an important opportunity to evaluate a novel treatment approach using a DNA vaccine platform to increase immune activation by generating a robust in-vivo T cell response, especially in the tumor, and potentially decreasing tumor recurrence in HPV positive head and neck cancer patients."

INO-3112, an active immunotherapy targeting HPV 16/18 combined with a DNA plasmid for IL-12 as an immune activator, is designed to activate patients' immune responses to specifically target and kill HPV associated tumors. This open label phase I/IIa study has fully enrolled twenty-two subjects with HPV-positive head and neck squamous cell carcinoma and is intended to assess the safety, tolerability, and immunogenicity of INO-3112 in two treatment groups.

Additionally, the study is evaluating the anti-tumor response and progression free survival of patients. The first group

enrolled six subjects who were treated with INO-3112 before and after resection of their tumor. One subject withdrew consent after surgery, leaving five evaluable subjects in this group. All of these subjects received one dose of INO-3112 (averaging 14 days and ranging 7 to 28 days) prior to definitive surgery plus three additional doses post-surgery. The second group enrolled sixteen subjects who received four doses of INO-3112 after at least two months following completion of definitive chemoradiation or surgery and adjuvant chemoradiation therapy.

This poster presentation provided immune response and disease free survival data from the first treatment group. CD8+ and FoxP3 T cell expression were evaluated in tumor samples obtained before and after surgery. In addition, ELISpot analysis was performed to determine the number of T cells capable of secreting IFN- γ in response to HPV antigen stimulation. Four of five subjects had robust T cell response as measured by blood ELISpot assay and the same four subjects also showed an average increase of 60% of CD8+ to FoxP3 ratio measured by immunohistochemistry post vaccination, demonstrating increased infiltration of CD8+ T cells as well as reduction of regulatory T cells measured by FoxP3 expression in tumor tissue. These four subjects remained disease free with follow-up ranging from nine to 24 months to date. One subject with only a marginal increase in ELISpot response magnitude to HPV and no increase in CD8+/FoxP3 ratio in tumor tissue post INO-3112 developed progressive disease at 11 months post-treatment.

Overall the characteristics of these immune response data mirrored those previously observed in a phase IIb clinical study of VGX-3100 for HPV-associated cervical dysplasia. In that study, strong CD8+ T cell immune responses were

positively correlated with achievement of primary and secondary efficacy endpoints. VGX-3100 is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions as well as the virus which caused the disease.

Inovio is continuing subject monitoring and comprehensive immune analyses for both cohorts of this study and expects multiple reports of additional data throughout 2017.

In August 2015, Inovio licensed INO-3112 to MedImmune, the global biologics research and development arm of AstraZeneca, for an upfront payment of \$27.5 million, \$700 million in potential development and commercial milestone payments, and royalties on INO-3112 product sales.

About HPV-Caused Head & Neck Cancer

Human papillomavirus (HPV) is the most common sexually transmitted disease in the United States, currently infecting about 79 million Americans. HPV is known to play a major role in the development of head and neck cancers, which include cancers of the oral cavity, oropharynx, nose/nasal passages and larynx. In 2016 an estimated 48,330 persons will get oral cavity or oropharyngeal cancer in the U.S. New cases of head and neck cancer occur nearly three times more often in men as in women. Incidence rates of head and neck cancers have been on the rise, especially HPV-associated oropharyngeal cancer in men, and are expected to continue growing.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:

Bernie Hertel
+1 858 410 3101
bhertel@inovio.com

Minera IRL – More shenanigans, and now a news release is due this week

Minera IRL {BVLP: MIRL} previously listed on the TSX Venture, AIM, and Lima Stock Exchanges is currently trying to list on the Canadian Stock Exchange (CSE).

Following the management civil war last year resulting in the de-listing on all exchanges, it was thought all was now moving forward, but rumours began to circulate of another boardroom coup last week.

Deja vu at Minera IRL?

A year ago the management and board of **Minera IRL** were engaged in a civil war, that tore the company apart, and resulted in the company being de-listed from the AIM, Toronto, and Lima Stock Exchanges.

The final outcome was that Darry Hodges and his team eventually left the board, after Diego Benavides, CEO of the Peruvian subsidiary, resisted the loss of the mine, and won the day.

Diego and new CEO Frank O'Kelly recently presented at the AMA presentation in London, and all seemed on track.

Last week rumours surfaced that a new board member was keen on asset stripping the Ollachea Mine from the shareholders.

After a meeting in Peru it was confirmed all the large Peruvian shareholders are going to vote down the resolutions in the hastily arranged AGM at the end of this month.

It has now been stated that the board will issue a statement this week! We have to hope they confirm all is still on track!

We await the next news with interest and will post an update when we have more news.

Barkerville acquires additional Crown land in B.C.

Barkerville Gold Mines Ltd. {TSX.V: BGM} announced that it has entered into a Mining Claim Acquisition Agreement pursuant to which Barkerville can acquire a 100% interest in Crown Grant 35F located in the Cariboo Mining District, British Columbia, in exchange for (a) an aggregate of CDN\$300,000; and (b) an aggregate of 254,237 common shares of Barkerville issuable to the vendor of the Property.

Barkerville Acquires Additional Crown Grant in BC

TORONTO, ON – November 11, 2016 – **Barkerville Gold Mines Ltd.** {TSX.V: BGM} is pleased to announce that it has entered into a Mining Claim Acquisition Agreement pursuant to which Barkerville can acquire a 100% interest in Crown Grant 35F located in the Cariboo Mining District, British Columbia, in

exchange for (a) an aggregate of CDN\$300,000; and (b) an aggregate of 254,237 common shares of Barkerville issuable to the vendor of the Property.

The issuance of the common shares pursuant to the Mining Claim Acquisition Agreement and the Relationship Agreement are subject to receipt of all necessary approvals, including that of the TSX Venture Exchange and will be subject to a statutory hold period of four months and one day from the date of issuance.

For further information on Barkerville Gold Mines Ltd., please contact:

Chris Lodder
President & Chief Executive Officer
Suite 400-365 Bay Street
Toronto, Ontario, Canada
cloodder@barkervillegold.com

Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death

Inovio Pharmaceuticals, {NASDAQ: INO} today announced that Inovio and its collaborators have published results in *Nature Partner Journals (npj) Vaccines* demonstrating that its Zika

DNA vaccine (GLS-5700) protected animals from infection, brain damage and death.

Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death.

PLYMOUTH MEETING, Pa. – November 10, 2016 – **Inovio Pharmaceuticals, {NASDAQ: INO}** today announced that Inovio and its collaborators have published results in Nature Partner Journals (npj) Vaccines demonstrating that its Zika DNA vaccine (GLS-5700) protected animals from infection, brain damage and death.

In this study 100% of GLS-5700 vaccinated animals were protected from Zika infection after exposure to the virus. In addition, vaccinated mice were protected from degeneration in the cerebral cortex and hippocampal areas of the brain while unvaccinated mice showed significant degeneration of the brain after Zika infection.

Prior preclinical studies have tested potential Zika vaccine candidates in animal models involving normal mice and non-human primates that are naturally resistant to Zika. While providing useful immunology data, they cannot provide relevant evidence of an effective means of controlling the spread or medical impacts of this disease by vaccination. In addition to reporting immunogenicity in such Zika-resistant species, this paper represents the first published research to also analyze a Zika vaccine using the special transgenic murine strain A129 lacking interferon alpha and beta receptors (IFNAR-/-), making them highly susceptible to Zika infection and disease.

Taking this extra step provided data on how vaccine-generated immune responses could protect against a lethal viral challenge and demonstrates the benefit a Zika vaccine might provide in people.

Dr. J. Joseph Kim, President and CEO of Inovio, said, “We clearly demonstrated the power and speed of our product development platform when we and our collaborators moved our Zika vaccine from the bench to human clinical studies in less than six months, a vaccine industry record. We’re pleased to now build further evidence of the potential utility of our product.”

“Our results support the critical importance of immune responses for both preventing infection as well as ameliorating disease caused by the Zika virus” said lead researcher **David B. Weiner, Ph.D., Executive Vice President and Director of the Vaccine Center at The Wistar Institute** and the W.W. Smith Charitable Trust Professor in Cancer Research at Wistar. Dr. Weiner is also a member of Inovio’s board of directors and chairs its scientific advisory board. “As the threat of Zika continues, these results further encourage the study of this vaccine as a preventative approach for protecting humans.”

This study demonstrated that Inovio’s synthetic DNA vaccine expressed antigens specific to Zika and generated robust antigen-specific and neutralizing antibody and T cell responses in mouse and non-human primate models. Moreover, the study also demonstrated that GLS-5700 provided protection against the disease and death in Zika-susceptible A129

transgenic mice while also being neuroprotective, meaning the disease was unable to spread to the brain. This is especially important given the risk that babies born with the disease have of developing microcephaly, a birth defect resulting in an abnormally small head and that may prevent the brain from developing properly.

This Zika vaccine was developed in a collaboration between Inovio Pharmaceuticals, Inc., The Wistar Institute, and GeneOne Life Science Inc. and is currently in two human clinical studies. Inovio expects to report phase I data before the end of this year from the first 40-subject study being conducted in Miami, Philadelphia and Quebec City.

In August, the companies initiated a second study of GLS-5700 in 160 subjects in Puerto Rico. The CDC estimates that Zika will infect more than 25 percent of the Puerto Rican population by the end of the year, providing the potential for this study's placebo control design to provide exploratory signals of vaccine efficacy in 2017.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells *in vivo* in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV

Research Program, and Laval University.

For more information, visit the corporate website
www.inovio.com

CONTACT:

Bernie Hertel
Inovio Pharmaceuticals
+1 858 41 3101
bhertel@inovio.com

Condor Gold Starts Scout Drilling Work On Nicaragua's La India Project

Condor Gold {AIM: CNR} on Thursday said it has started scout drilling work on the La India gold project located in Nicaragua, Central America.

The programme is designed to demonstrate the upside of the entire project.

Condor Gold Starts Scout Drilling Work On Nicaragua's La India Project

Condor Gold {AIM: CNR} on Thursday said it has started scout drilling work on the La India gold project located in Nicaragua.

The programme is designed to demonstrate the upside of the entire project. It will seek to expand mineralisation at the El Cacao and Cristalito-Tatescame targets and test for mineralisation at the Andrea Vein, which has never before been tested.

"I am delighted that we have now prioritised several highly promising targets and are commencing scout drilling at El Cacao and Cristalito-Tatescame. Although each is currently relatively small, we believe that both have excellent potential to host much larger gold resources," said **Mark Child, Condor's chief executive.**

Inovio Pharmaceuticals presentation well received by investors in London

Inovio Pharmaceuticals VP of IR and Communications **Bernie Hertel** presented to the **City Investors Circle** last night in London, and his presentation was very well received by a knowledgeable audience.

The format was a boardroom dinner.

Attendees at our recent dinner presentation for Inovio Pharmaceuticals



Avalon Completes Non-Brokered Private Placement for Gross Proceeds of \$1 Million

Avalon Advanced Materials Inc. {TSX: AVL} announced that it has completed a non-brokered private placement today consisting of 4,545,454 flow-through shares at a price of \$0.22 per share for gross proceeds of \$1,000,000.

Avalon Completes Non-Brokered Private Placement for Gross Proceeds of \$1 Million

Toronto, ON – **Avalon Advanced Materials Inc.** (TSX: AVL) is pleased to announce that it has completed a non-brokered private placement today consisting of 4,545,454 flow-through shares at a price of \$0.22 per share for gross proceeds of \$1,000,000.

In conjunction with this private placement Avalon paid finder's fees of \$60,000 and issued 272,727 non-transferrable finder's warrants, with each finder's warrant being exercisable to acquire one common share of the Company at a price of \$0.25 for a period of 24 months from today.

Pursuant to Canadian securities laws, the securities issuable under this private placement are subject to a hold period

which expires on March 8, 2017. The proceeds from this offering will be used primarily to advance exploration work, including drilling, on the Company's Separation Rapids Lithium Project.

This press release is not an offer of securities for sale in the United States. The securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and may not be offered or sold in the United States or to US persons (as defined in Regulation S under the US Securities Act) absent registration or an applicable exemption from registration.

About Avalon Advanced Materials Inc.

Avalon Advanced Materials Inc. (formerly Avalon Rare Metals Inc.) is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology.

The Company has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback,

please e-mail the Company at ir@AvalonAM.com

or

phone Don Bubar, President & CEO at +1 416 364 4938.

This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements related to how the Company plans to use the net proceeds from the Private Placement, and that proceeds from this offering will be used primarily to advance exploration work, including drilling, on the Company's Separation Rapids Lithium Project. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "potential", "scheduled", "anticipates", "continues", "expects" or "does not expect", "is expected", "scheduled", "targeted", "planned", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be" or "will not be" taken, reached or result, "will occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avalon to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. Although Avalon has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to market conditions, and the possibility of cost overruns or unanticipated costs and

expenses as well as those risk factors set out in the Company's current Annual Information Form, Management's Discussion and Analysis and other disclosure documents available under the Company's profile at www.SEDAR.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements have been provided for the purpose of assisting investors in understanding the Company's plans and objectives and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements. Avalon does not undertake to update any forward-looking statements that are contained herein, except in accordance with applicable securities laws.

130 Adelaide St. W, Suite 1901
Toronto, ON M5H 3P5

+1 416 364 4938
ir@AvalonAM.com

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

Inovio Pharmaceuticals, {NASDAQ: INO} announced that the Company will participate at three forthcoming investment conferences in New York.

Global Mizuho, Stifel, and Piper Jaffray.

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

2016-11-04 05:00 PT – News Release

PLYMOUTH MEETING, Pa., Nov. 04, 2016 **Inovio Pharmaceuticals, {NASDAQ: INO}** today announced that the Company will participate at the following upcoming investment conferences:

Global Mizuho Investor Conference (MIC)

One-on-one meetings only

Dr. Niranjan Sardesai, COO

November 14, 2016

Omni Berkshire Place, New York, NY

Stifel 2016 Healthcare Conference

Presentation

Dr. Niranjan Sardesai, COO

11:00AM ET, November 15, 2016

Lotte New York Palace, New York, NY

28th Annual Piper Jaffray Healthcare Conference

Fireside chat

Dr. J. Joseph Kim, President & CEO

11:30AM ET, November 29, 2016

Lotte New York Palace, New York, NY

Live and archived versions of the presentation and fireside chat will be available through the “Webcast” tab on Inovio’s home page at www.inovio.com

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future

payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended June 30, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Contact:

Bernie Hertel

+1 858 410 3101

bhertel@inovio.com

StoreDot unveil their latest two minute phone charger

StoreDot, the Israel based advanced battery developer and manufacturer has just unveiled a two minute phone charger, and demonstrated it on a Samsung Galaxy S5.

From virtually expired to fully charged in two minutes is impressive, although two recharges a day will be required, the sheer speed of the charge overcomes that.

The full story may be read here:

To read the full article please [CLICK HERE](#)

<http://www.blitton.com/smartphone-battery-from-storedot/>

POET Technologies CEO issues shareholder letter after 36c

financing

Poet Technologies Inc. {TSX.V: PTK} has published a letter to shareholders from the company's chief executive officer, Dr. Suresh Venkatesan.

This is to describe the rationale behind the 36c financing which has disappointed many shareholders.

Poet provides rationale for \$12.52-million offering

Dr. Suresh Venkatesan reports

POET TECHNOLOGIES ISSUES CEO LETTER TO SHAREHOLDERS

Poet Technologies Inc. has published the following letter to shareholders from the company's chief executive officer, Dr. Suresh Venkatesan.

Nov. 2, 2016

To our shareholders,

Following today's close of our public offering, which generated aggregate gross proceeds of \$12,528,000, I would like to address the concerns expressed by several of our shareholders and expand further on the company's rationale for raising additional capital at this time. Let me emphasize that the decision to raise capital was made following careful evaluation and consideration by Poet's executive management team and the board. Our increased manufacturing capability in Singapore fundamentally changes the company's capital

investment priorities. We therefore collectively determined that the offering was essential to make critical investments in multiple areas of the business.

First, it is important for the company to gain greater control over its own destiny as we continue to advance technology and product development related to Poet's integrated optical platform technology, including both the VCSEL and detector. As previously communicated, we have completed transfer from the lab and are beginning to develop and optimize our integrated optical platform technology in a high-volume large wafer-scale manufacturing foundry.

As we continue product development of the Poet platform technology, we anticipate bringing key capabilities in-house for the most time-sensitive aspects of technology development to help avoid future delays associated with third party vendors. These delays relate to the timing and scheduling of Poet's manufacturing requirements in the production plans of the vendors.

As a small company with limited prototype runs, we do not represent a large current account to these vendors, and lead times can sometimes extend to months. We believe that investments in the development of multiple sources for our epitaxial wafers and in capital equipment will allow us to accelerate the cycles of learning that are needed to produce prototype devices that meet distinct specifications.

Second, we believe the company has a significant opportunity to drive meaningful near-term revenue growth through its

recently acquired DenseLight business. The capital we raised should allow us to invest in expanded sales and product development of the DenseLight product portfolio, including the introduction of competitive new products for the sensing and lasering markets.

There is strong market demand for these products today, and it is imperative that the company have sufficient working capital to effectively participate in these markets and capture market share to drive near-term revenue growth. The success of our DenseLight business should provide the company with established sales channels and customer relationships that will ultimately be essential to the commercialization of the Poet platform technology. Additionally, it should provide the potential to accelerate time-to-market once we reach that stage of commercialization.

Poet is no longer solely a research and development company. We have a manufacturing facility and infrastructure that enable us to internalize manufacturing of our technology. We must continue to drive investment in technology and product development to achieve commercialization and begin capitalizing on the full revenue potential of our existing technology platform and infrastructure.

Third, it is important that Poet maintain a strong balance sheet as we make the investments outlined above – investments that are required to support the evolution of our business model. It is increasingly clear that we must first demonstrate production-ready products before pursuing potential licensing opportunities, since potential licensees require evidence beyond laboratory demonstrations as key proof points of commercialisation prior to making any significant investment.

As we continue to grow the company and its product portfolio, we anticipate having an increasing number of opportunities to pursue larger customers, as well as partners. A strong balance sheet is extremely important for exhibiting sustainability and being viewed as a reliable supplier or collaborator.

Following the offering, Poet is now in a better position to operate from a position of strength and preserve its strategic focus on building a long-term, sustainable business. Also in support of our efforts to prudently manage financial resources, we are implementing cost-reduction measures, including a temporary decrease in salaries of all Poet executives in the United States. These actions will help to preserve cash and maximize the amount of resources available to finance technology development.

Lastly, let me address the pricing of the offering. *The offering price is not an indication of management's view on the long-term value of the company. In fact, we are now more encouraged about the future opportunities and prospects of our business. However, the pricing of any public offering is determined by investor demand in co-ordination with the investment banks placing the offering, which reflects a variety of factors that are not necessarily related to the trading price of the stock when the offering is initiated.*

That said, we acknowledge and recognise the concerns raised by shareholders resulting from the pricing of the company's public offering, which followed extensive marketing efforts we made in Canada, the United States and Europe. As outlined above, we felt it was important to secure the necessary funds

today that would enable us to make critical investments in our business and product development. We believe without this investment the company's ability to ramp our existing products, as well as the methods by which we pursue full commercialization of the Poet technology, would be constrained.

The certainty of a raise today, versus the unknown market environment that could possibly be faced in the future, warranted us to proceed with the raise. Additionally, as part of this offering, we were able to secure sophisticated institutional investors, which we expect to provide expanded awareness for Poet in the U.S. and other international financial markets.

In closing, we as a management team and our board are greatly appreciative for the significant investment each of our shareholders has made in Poet, as well as their continued passionate interest and support. We remain steadfast in our commitment to build a long-term, sustainable business that can potentially increase the value and valuation of our company.

Although the path and timelines to achieve full commercialisation may have evolved from what was originally envisioned, I am confident that we are better positioned today to achieve our goals and vision. I would like to personally thank our shareholders for your long-standing and continued support of Poet Technologies.

Sincerely,

Dr. Suresh Venkatesan

Chief executive officer, Poet Technologies

About Poet Technologies

Poet (planar optoelectronic technology) is a developer of optoelectronics and Photonic fabrication processes and products. Photonics integration is fundamental to increasing functional scaling and lowering the cost of current Photonic solutions. Poet believes that its advanced optoelectronics process platform enables substantial improvements in energy efficiency, component cost and size in the production of smart optical components, the engines driving applications ranging from data centres to consumer products to military applications. Silicon Valley-based Poet's patented module-on-a-chip process, which integrates digital, high-speed analog and optical devices on the same chip, is designed to serve as an industry standard for smart optical components.

We seek Safe Harbor.

POET Technologies Completes C\$12.5 Million Public Offering of Units at 36c

POET Technologies Inc. {TSX.V: PTK} announced today that it has completed its previously announced public offering of units of the Company ("Units") to raise aggregate gross proceeds of C\$12.5 million (the "Offering").

A total of 34,800,000 Units were issued at a price of C\$0.36 per Unit.

Comment

I nearly fell off my chair when I saw the price of this fundraising.

Seriously not impressed, some shareholders feel gutted, and that's entirely understandable.

The shareprice is now 31c, and that's not a surprise to me after this fiasco. The share price has fallen from 78c to 31c in less than a month!

Peter Copetti leaving was a surprise to me and now my worst fears have been realised, he is a capital markets guy who knows what he's doing.

POET Technologies Completes C\$12.5 Million Public Offering of Units

November 2nd, 2016

SAN JOSE, Calif., Nov. 2, 2016 – **POET Technologies Inc.** {TSX.V: PTK} announced today that it has completed its previously announced public offering of units of the Company (“Units”) to raise aggregate gross proceeds of C\$12.5 million (the “Offering”).

A total of 34,800,000 Units were issued at a price of C\$0.36 per Unit pursuant to a placement agency agreement (the “Agency Agreement”) dated October 28, 2016 among the Company, Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, as lead agent and lead book-running manager (and sole agent in the United States) and Cormark Securities Inc. as lead manager in Canada.

Each Unit contained one common share of the Company (each a "Share") and one common share purchase warrant (each a "Warrant"), with each Warrant exercisable by the holder thereof to acquire one additional Share at a price of C\$0.52 per Share for a period of 60 months following the closing of the Offering.

The Offering was carried out in each of the provinces of Canada (other than Quebec) pursuant to a prospectus supplement dated October 28, 2016 (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated October 6, 2016, and in the United States pursuant to a registration statement on Form F-10 (which includes the short form base shelf prospectus). The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, increasing working capital, research and development, further product and sales development, as well as potential business or intellectual property acquisitions in support of strategic growth.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, Units, Shares or Warrants in any state or province in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state, province, or other jurisdiction.

The Prospectus Supplement (and any marketing materials) relating to the offering are available free of charge on the SEDAR website at www.sedar.com, on the SEC's website at www.sec.gov and on the Company's website at www.poet-technologies.com and electronic copies may also be obtained from the offices of H.C. Wainwright & Co., LLC at 430

Park Avenue, 4th Floor, New York, New York 10022 or by emailing placements@hcwco.com. The Offering was only carried out by means of the short-form base shelf prospectus and the Prospectus Supplement.

About POET Technologies Inc.

POET (Planar Opto-Electronic Technology) is a developer of opto-electronics and Photonic fabrication processes and products. Photonics integration is fundamental to increasing functional scaling and lowering the cost of current Photonic solutions. POET believes that its advanced opto-electronics process platform enables substantial improvements in energy efficiency, component cost and size in the production of smart optical components, the engines driving applications ranging from data centers to consumer products to military applications. Silicon Valley-based POET's patented module-on-a-chip process, which integrates digital, high-speed analog and optical devices on the same chip, is designed to serve as an industry standard for smart optical components.

More information may be obtained at www.poet-technologies.com

ON BEHALF OF THE BOARD OF DIRECTORS

John F. O'Donnell, Secretary

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Radisson Mining intersects 5 gpt gold over 5 metres in new zone at O'Brien

Radisson Mining Resources Inc. {TSX.V: RDS} announced gold assay results from the last three holes of the summer 2016 drill program at the O'Brien gold project along the Abitibi Greenstone Belt, Quebec, Canada.

Of particular note was an intersection of 5 gpt AU over 5 metres.

Rouyn-Noranda, Quebec, November 2, 2016: **Radisson Mining Resources Inc.** {TSX.V: RDS} is pleased to announce gold assay results from the last three holes of the summer 2016 drill program at the O'Brien gold project along the Abitibi Greenstone Belt, Quebec.

Mario Bouchard, President and CEO commented: “We are delighted with the consistency of the results obtained within gold mineralised zone intersected. The quality of the asset owned at 100% by Radisson in a world-renowned mining camp is underpinned by these results. Our approach to increase mineral resources through additional drilling is also validated. In parallel, the two visible gold intersections obtained within the Pontiac Group sedimentary rocks in drill hole OB-16-11 continues to fuel the potential for additional discovery in this sector. To this extent, “Orevision” Induced polarisation survey was completed this week in collaboration with Abitibi Geophysics Inc. Results are currently being compiled and should generate additional exploration drilling targets in the Pontiac Group sedimentary package”.

Hole OB-16-12 was drilled in historic resources extension of “F Zone” between the 36E area and the old O'Brien mine (See figure 1). Drill holes OB-16-11 and OB-16-9 were completed in ore shoot extensions of 36E and Kewagama areas (See figure 2). Two out of the three drill holes have intersected visible

gold.

- Drill hole OB-16-12 intersected 4.99 g/t Au over 5.0 m (within an intersection of 3.00 g/t Au over 16.00 m) at a depth of 520 metres in extension of historic “F zone” between the old O’Brien mine and 36E area (See figure 1).
- Drill hole OB-16-11 intersected 4.72 g/t Au over 1.0 m at a depth of 587 m. Note that due to deviation the hole did not intersect targeted area within the Volcanic Piché group.
- Drill hole OB-16-9 intersected 3.93 g/t Au over 2.0 m at a depth of 503 m and 3.20 g/t Au over 3.0 m in vertical extension of current mineral resources.
- Pontiac Group sedimentary package was crossed by the 3 drill holes. Hole OB-16-11 intersected visible gold at a depth of 315.5 m within the Pontiac Group and graded 3.82 g/t Au over 1.5 m.

Note; Results are presented downhole width; true width is estimated between 55 to 70% of downhole width.

10,000 metres drill program update

In mid-September, the corporation started an additional drill program of 10,000 metres. Up to date, 3 drill holes were completed for a total of 1,826 metres. The main focus of this new drill program remains to increase inferred resources by targeting the extension of ore shoots in the Piché volcanic group from surface to a depth of 500 m.

All drill holes are completed with a South North orientation and should also cross the Pontiac Group sedimentary package.

Historic review and data compilation update

The review of historic drill core is underway since September. Many samples were collected and sent for assaying. Results are pending.

All drill cores in this campaign are NQ in size. Analyses were completed on sawn half-cores, with the second half kept for future reference. The samples were analysed using standard fire assay procedures with AA finish at Techni-Lab Actlabs in Ste-Germaine-Boulé in Abitibi, Quebec.

Samples yielding a grade higher than 5 g/t were analysed a

second time by fire assay with gravimetric finish at the same laboratory. Assays containing visible gold were reanalysed with metallic sieve procedure. Standard reference materials and blank samples were inserted prior to shipment for quality assurance and quality control (QA/QC) program.

Qualified Person

Tony Brisson, Geo., independent consultant, acts as a Qualified Person as defined in National Instrument 43-101 and has reviewed and approved the technical information in this press release.

About Radisson Mining Resources Inc.

Radisson is a Quebec-based mineral exploration company. The O'Brien project, cut by the regional Larder-Lake-Cadillac Fault, is Radisson's flagship asset. The project hosts the former O'Brien Mine, considered to have been the Abitibi Greenstone Belt's highest-grade gold producer during its production (1,197,147 metric tons at 15.25 g/t Au for 587,121 ounces of gold from 1926 to 1957; InnovExplor, April 2015).

For more information on Radisson, visit our website at www.radissonmining.com

Contact:

Mario Bouchard

President and CEO

819-277-6578

mbouchard@radissonmining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This press release may contain certain forward-looking information. All statements included herein, including the scheduled Closing date, but other than statements of historical fact, is forward-looking information and such

information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward looking information can be found in Radisson's disclosure documents on the SEDAR website at www.sedar.com

Bitcoin celebrates its 8th Birthday

Bitcoin celebrated its 8th birthday on the 31st October.

In celebration, during the month of October, **Bitcoin** increased in value from \$614 to \$724, a phenomenal success.